004310.KS
Hyundai Pharmaceutical Co., Ltd.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 6,680.00
−2.91%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 207.0B | 191.8B | 175.7B | 180.8B | 162.7B |
| Cost of Revenue | 133.4B | 113.6B | 102.4B | 105.5B | 93.9B |
| Gross Profit | 73.6B | 78.2B | 73.4B | 75.2B | 68.8B |
| Operating Expenses | |||||
| R&D Expense | 16.7B | 17.7B | 15.3B | 12.0B | 8.4B |
| SG&A Expense | 30.7B | 29.9B | 30.9B | 31.1B | 28.2B |
| General & Admin Expense | 10.9B | 10.5B | 10.3B | 10.4B | 10.1B |
| Selling & Marketing Expense | 19.8B | 19.4B | 20.6B | 20.7B | 18.1B |
| Other Expenses | 25.5B | 45.0B | 26.9B | 25.3B | 24.3B |
| Total Operating Expenses | 68.3B | 74.9B | 73.2B | 68.3B | 60.9B |
| Cost and Expenses | 201.4B | 187.6B | 175.6B | 173.8B | 154.7B |
| Operating Income (EBIT) | 5.4B | 3.3B | 180.9M | 6.9B | 8.0B |
| Non-Operating | |||||
| Interest Income | 86.6M | 34.6M | 165.8M | 742.9M | 392.9M |
| Interest Expense | 1.9B | 1.9B | 2.0B | 1.9B | 1.2B |
| Net Interest Income | (1.8B) | (1.9B) | (1.8B) | (1.2B) | (767.9M) |
| Other Non-Op Income/Expense | (621.8M) | (992.5M) | (1.9B) | 1.1B | (2.3B) |
| Non-Operating Income (excl Interest) | (520.0K) | (33.5M) | (72.8M) | (3.0B) | 1.2B |
| EBT (Pre-Tax Income) | 4.7B | 2.3B | (1.7B) | 8.0B | 5.7B |
| Income Tax Expense | 1.3B | (209.5M) | (1.2B) | 1.9B | 5.8B |
| Bottom Line | |||||
| Net Income | 3.6B | 2.5B | (574.9M) | 6.1B | (164.6M) |
| Earnings from Cont. Ops | 3.6B | 2.5B | (574.9M) | 6.1B | (164.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 3.6B | 2.5B | (574.9M) | 6.1B | (164.6M) |
| Per Share | |||||
| Basic EPS | ₩121 | ₩96 | (₩22) | ₩226 | (₩6) |
| Diluted EPS | ₩121 | ₩96 | (₩22) | ₩226 | (₩6) |
| Revenue Per Share | ₩6,697 | ₩7,338 | ₩6,850 | ₩6,668 | ₩5,850 |
| Shares | |||||
| Basic Shares Outstanding | 30.9M | 26.1M | 25.7M | 27.1M | 27.8M |
| Diluted Shares Outstanding | 30.9M | 26.1M | 25.7M | 27.1M | 27.8M |
| Profitability Metrics | |||||
| EBITDA | 10.4B | 7.6B | 3.9B | 13.2B | 10.0B |
| D&A | 4.9B | 4.3B | 3.7B | 3.3B | 3.3B |
| EBIT | 5.5B | 3.3B | 253.7M | 9.9B | 6.7B |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Aug 1, 2026